Nuvalent, Inc. (NUVL)
94.77
-2.29
(-2.36%)
USD |
NASDAQ |
Mar 20, 16:00
94.78
+0.01
(+0.01%)
After-Hours: 20:00
Nuvalent Research and Development Expense (Quarterly) : 67.80M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Glaukos Corp. | 43.65M |
| Edgewise Therapeutics, Inc. | 43.07M |
| Cogent Biosciences, Inc. | 74.38M |
| Neurocrine Biosciences, Inc. | 258.20M |
| BioMarin Pharmaceutical, Inc. | 192.41M |